These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25164277)

  • 61. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
    Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
    J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.
    Dajani A; AbuHammour A
    Saudi J Gastroenterol; 2016; 22(2):91-105. PubMed ID: 26997214
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo.
    Xiang C; Chen X; Yao J; Yang N; Yu J; Qiu Q; Zhang S; Kong X; Zhao L; Fan ZC; Yu P; Teng YO
    Eur J Med Chem; 2023 Sep; 257():115510. PubMed ID: 37269672
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
    Billin AN
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1465-71. PubMed ID: 18808307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
    Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
    Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
    Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
    Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
    Plutzky J
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S12-4. PubMed ID: 17935055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 71. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.
    Gross B; Pawlak M; Lefebvre P; Staels B
    Nat Rev Endocrinol; 2017 Jan; 13(1):36-49. PubMed ID: 27636730
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Malik A; Nadeem M; Malik MI
    Clin J Gastroenterol; 2021 Dec; 14(6):1579-1586. PubMed ID: 34370218
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PPAR-α agonists are still on the rise: an update on clinical and experimental findings.
    Ferri N; Corsini A; Sirtori C; Ruscica M
    Expert Opin Investig Drugs; 2017 May; 26(5):593-602. PubMed ID: 28343425
    [TBL] [Abstract][Full Text] [Related]  

  • 74. NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root.
    Colca J
    Expert Opin Investig Drugs; 2020 Feb; 29(2):191-196. PubMed ID: 31928475
    [No Abstract]   [Full Text] [Related]  

  • 75. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
    Colca JR; McDonald WG; Adams WJ
    Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
    Issa D; Wattacheril J; Sanyal AJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases.
    Gao A; Cayabyab FS; Chen X; Yang J; Wang L; Peng T; Lv Y
    DNA Cell Biol; 2017 Dec; 36(12):1050-1061. PubMed ID: 28945101
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.
    Cooreman MP; Butler J; Giugliano RP; Zannad F; Dzen L; Huot-Marchand P; Baudin M; Beard DR; Junien JL; Broqua P; Abdelmalek MF; Francque SM
    Nat Commun; 2024 May; 15(1):3962. PubMed ID: 38730247
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [THE USE OF REMAXOL IN THE TREATMENT OF METABOLIC SYNDROME IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND DIABETES MELLITUS 2 TYPE].
    Dudorenko SV; Kovalenko AL; Prokopenko SM; Belogurova EV
    Eksp Klin Gastroenterol; 2016; (6):89-94. PubMed ID: 30280846
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications?
    Sahebkar A; Watts GF
    Curr Opin Lipidol; 2017 Jun; 28(3):282-283. PubMed ID: 28459766
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.